Humacyte Shares Tumble As FDA Review of Vascular Trauma Treatment Needs More Time
Humacyte shares fell 20% in after-hours trading Friday after the Food and Drug Administration said it will require more time to review a proposed treatment for vascular trauma.Shares were trading around $6.33. The stock has more than doubled in 2024.The biotechnology company disclosed that the FDA will need more time to review a biologic license application for the acellular tissue engineered vessel in the vascular trauma indication. The acellular tissue engineered vessel trauma program application was submitted to the FDA in December.